• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?基于生理学的药代动力学模型对来氟米特和特立氟胺预测的反应——是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):564. doi: 10.1002/psp4.12036. Epub 2015 Oct 9.
2
Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?用于预测来氟米特和特立氟胺的基于生理的药代动力学模型：是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):563. doi: 10.1002/psp4.12033. Epub 2015 Oct 9.
3
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.类风湿关节炎患者中来氟米特处置的半生理药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.
4
Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.来氟米特治疗腹膜透析终末期肾病炎症性关节炎：一项药代动力学和药物遗传学研究。
Ann Pharmacother. 2013 Mar;47(3):e15. doi: 10.1345/aph.1R542. Epub 2013 Feb 27.
5
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.来氟米特局部给药治疗类风湿性关节炎：在关节炎大鼠模型中评价托法替布的局部组织沉积及其抗炎作用。
Drug Dev Ind Pharm. 2016;42(2):254-62. doi: 10.3109/03639045.2015.1044906. Epub 2015 May 26.
6
Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.肝微粒体细胞色素P450酶和钠/胆汁酸共转运体的抑制会加重来氟米特诱导的肝毒性。
Acta Pharmacol Sin. 2016 Mar;37(3):415-24. doi: 10.1038/aps.2015.157. Epub 2016 Jan 25.
7
Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.来氟米特和特立氟胺：改变嘧啶代谢以治疗自身免疫性疾病。
Expert Rev Clin Pharmacol. 2015 May;8(3):315-20. doi: 10.1586/17512433.2015.1019343. Epub 2015 Feb 24.
8
On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.来氟米特与特立氟胺在受体腔内的相互作用——核磁共振研究与能量计算
J Mol Model. 2015 May;21(5):105. doi: 10.1007/s00894-015-2643-z. Epub 2015 Apr 8.
9
Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.特立氟胺（奥巴捷）。多发性硬化症：只是来氟米特的一种代谢产物。
Prescrire Int. 2015 Mar;24(158):61-4.
10
Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.抗炎药物来氟米特及其代谢物特立氟胺在体内和体外均能抑制非小细胞肺癌的增殖。
Toxicol Lett. 2018 Jan 5;282:154-165. doi: 10.1016/j.toxlet.2017.10.013. Epub 2017 Oct 16.

本文引用的文献

1
Individualization of leflunomide dosing in rheumatoid arthritis patients.类风湿关节炎患者来氟米特给药的个体化
Per Med. 2014 Jun;11(4):449-461. doi: 10.2217/pme.14.23.
2
Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?用于预测来氟米特和特立氟胺的基于生理的药代动力学模型：是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):563. doi: 10.1002/psp4.12033. Epub 2015 Oct 9.
3
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.类风湿关节炎患者中来氟米特处置的半生理药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.
4
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.来氟米特治疗多发性硬化症的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1025-35. doi: 10.1517/17425255.2013.800483. Epub 2013 May 17.
5
Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS.采用 LC-MS/MS 定量测定人血浆中的总游离特立氟胺（A77 1726）。
J Pharm Biomed Anal. 2011 May 15;55(2):325-31. doi: 10.1016/j.jpba.2011.01.034. Epub 2011 Feb 4.

Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?

作者信息

Hopkins A M, Foster Djr, Wiese M D, Upton R N

机构信息

University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences Adelaide, South Australia, Australia ; University of South Australia, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences Adelaide, South Australia, Australia.

University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences Adelaide, South Australia, Australia.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):564. doi: 10.1002/psp4.12036. Epub 2015 Oct 9.

DOI:10.1002/psp4.12036
PMID:26535156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4625860/
Abstract
摘要